Company intelligence / Profile preview

OM1

Boston, Massachusetts, USAom1.com ↗

Ownership: Private
Development stage: Commercial

Overview

OM1 provides advanced real-world data and AI-powered analytics solutions to support research, regulatory submissions, label expansions, post-market commitments, and personalized medicine. Its platforms are used by life sciences companies for evidence generation across the product lifecycle. The company has been recognized as a top innovator in RWE by Frost & Sullivan and collaborates with major pharmaceutical companies such as Eli Lilly on research projects.

Therapeutic areas: OncologyPulmonologyRare DiseasesDermatologyRheumatologyGastroenterologyCardiovascularNeurology
Industry: Biomedical IT and Biomedical Data Platforms

Partnerships

Collaborations with major pharmaceutical companies including Eli Lillyworks with providers and payers on real-world evidence initiatives

Beyond the preview

Go deeper on OM1.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OM1.

Explore the full profile